Development of Solid Lipid Nanoparticles (SLNs) for Poorly Soluble Drugs

In recent years, nanotechnology has significantly impacted various technological domains, especially drug delivery systems. As modern drug delivery techniques evolve, Solid Lipid Nanoparticles (SLNs) have emerged as a promising platform in the fields of biotechnology, hiomedical engineering, and nanomedicine for their potential in healthcare and diagnostics. SLNs address critical challenges in drug formulation, particularly the poor solubility and bioavailability of many newly developed drugs.Lipid-based nanoparticles have shown great promise in overcoming these limitations. Compared to other colloidal carriers, lipid nanoparticles are biocompatible. Biodegradable, and mainly composed of components generally recognized as safe (GRAS). Since their emergence in the early 1990s, SLNs have demonstrated their capability to surpass the shortcomings of traditional drug delivery systems. Many effective pharmaceutical formulations fail in clinical practice due to low absorption, high metabolism, wide systemic distribution, and poor bioavailability especially in the case of BCS Class II and IV drugs, peptides, and proteins. Instead of developing new drugs from scratch, repurposing existing drugsusing carriers like SLNs proves to be more cost-effective and efficient. SLNs consist of solid lipids such as triglycerides, waxes, and glyceride blends that remain solid at room and body temperature. They also contain surfactants and co-surfactants (0.5%-5%) for stabilization. The unique nanoscale size of SLNs (typically 50-200 nm) allows for reduced toxicity, sustained release, and protection against enzymatic degradation, Furthermore, their surfaces can be functionalized with ligands or polymers for targeted delivery, and both hydrophilic and lipophilic drugs can be efficiently incorporated into their matrices.Due to these attributes, SLNs offer a powerful and flexible nanocarrier system with applications in various therapeutic areas, especially for drugs with poor water solubility

Publication Details

Journal
International Journal of Pharmaceutical Research and Applications
Published
2025-05-01
DOI
https://doi.org/10.35629/4494-1005518528
Primary Topic
Plant Diversity and Evolution
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of Solid Lipid Nanoparticles (SLNs) for Poorly Soluble Drugs

International Journal of Pharmaceutical Research and Applications
Plant Diversity and Evolution
article

Development of Solid Lipid Nanoparticles (SLNs) for Poorly Soluble Drugs

article en

Abstract

In recent years, nanotechnology has significantly impacted various technological domains, especially drug delivery systems. As modern drug delivery techniques evolve, Solid Lipid Nanoparticles (SLNs) have emerged as a promising platform in the fields of biotechnology, hiomedical engineering, and nanomedicine for their potential in healthcare and diagnostics. SLNs address critical challenges in drug formulation, particularly the poor solubility and bioavailability of many newly developed drugs.Lipid-based nanoparticles have shown great promise in overcoming these limitations. Compared to other colloidal carriers, lipid nanoparticles are biocompatible. Biodegradable, and mainly composed of components generally recognized as safe (GRAS). Since their emergence in the early 1990s, SLNs have demonstrated their capability to surpass the shortcomings of traditional drug delivery systems. Many effective pharmaceutical formulations fail in clinical practice due to low absorption, high metabolism, wide systemic distribution, and poor bioavailability especially in the case of BCS Class II and IV drugs, peptides, and proteins. Instead of developing new drugs from scratch, repurposing existing drugsusing carriers like SLNs proves to be more cost-effective and efficient. SLNs consist of solid lipids such as triglycerides, waxes, and glyceride blends that remain solid at room and body temperature. They also contain surfactants and co-surfactants (0.5%-5%) for stabilization. The unique nanoscale size of SLNs (typically 50-200 nm) allows for reduced toxicity, sustained release, and protection against enzymatic degradation, Furthermore, their surfaces can be functionalized with ligands or polymers for targeted delivery, and both hydrophilic and lipophilic drugs can be efficiently incorporated into their matrices.Due to these attributes, SLNs offer a powerful and flexible nanocarrier system with applications in various therapeutic areas, especially for drugs with poor water solubility

International Journal of Pharmaceutical Research and ApplicationsVol. 10(5)
Openalex Percentile: Top 36%
Plant Diversity and Evolution
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Development of Solid Lipid Nanoparticles (SLNs) for Poorly Soluble Drugs · International Journal of Pharmaceutical Research and Applications (2025) | TGRS Research Map | TGRS